Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Sickle Cell-Related Pain Crises

Next Previous
Trial Profile

A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Sickle Cell-Related Pain Crises

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Crizanlizumab (Primary)
  • Indications Vaso-occlusive crisis
  • Focus Registrational; Therapeutic Use
  • Acronyms SUSTAIN
  • Sponsors Reprixys Pharmaceuticals Corporation; Selexys Pharmaceuticals

    • Most Recent Events

    • 12 Dec 2023 Results of pooled analysis from studies (NCT0189536, NCT03264989, NCT03474965 and NCT03814746 )in patients with SCD, presented at 65th Annual Meeting and Exposition of the American Society of Hematology.
    • 08 Dec 2020 Results (n=81) of post-hoc analysis assessing number of days of opioid use by patients in both the arms during 52 weeks follow-up period presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
    • 19 Nov 2020 According to a Novartis media release, data from this trial will be presented at 62nd American Society of Hematology (ASH) Annual Meeting & Exposition
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top